ZA976326B - Analogs of cationic proteins. - Google Patents

Analogs of cationic proteins.

Info

Publication number
ZA976326B
ZA976326B ZA9706326A ZA976326A ZA976326B ZA 976326 B ZA976326 B ZA 976326B ZA 9706326 A ZA9706326 A ZA 9706326A ZA 976326 A ZA976326 A ZA 976326A ZA 976326 B ZA976326 B ZA 976326B
Authority
ZA
South Africa
Prior art keywords
analogs
cationic proteins
cationic
proteins
Prior art date
Application number
ZA9706326A
Other languages
English (en)
Inventor
Thomas Charles Boone
Ellen Ngoi Yin Cheung
Susan Irene Hershenson
John David Young
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA976326B publication Critical patent/ZA976326B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
ZA9706326A 1996-07-19 1997-07-17 Analogs of cationic proteins. ZA976326B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68435396A 1996-07-19 1996-07-19

Publications (1)

Publication Number Publication Date
ZA976326B true ZA976326B (en) 1998-02-03

Family

ID=24747700

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9706326A ZA976326B (en) 1996-07-19 1997-07-17 Analogs of cationic proteins.

Country Status (11)

Country Link
US (4) US6211150B1 (fr)
EP (1) EP0938499A1 (fr)
AU (1) AU720232B2 (fr)
CA (1) CA2259163C (fr)
CZ (1) CZ399A3 (fr)
IL (1) IL127872A0 (fr)
NO (1) NO990059L (fr)
NZ (1) NZ333650A (fr)
SK (1) SK1499A3 (fr)
WO (1) WO1998003546A1 (fr)
ZA (1) ZA976326B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284143A1 (fr) * 2001-08-17 2003-02-19 Sifi S.p.A Procédé de préparation de formulations pharmaceutique contenant de la lactoferrine
RS54160B1 (sr) 2003-03-19 2015-12-31 Biogen Idec Ma Inc. Protein koji se vezuje za nogo receptor
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
WO2005035753A1 (fr) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite remplaçant une proteine fonctionnelle
EP1720564A1 (fr) * 2004-02-20 2006-11-15 Rinat Neuroscience Corp. Methodes de traitement de l'obesite ou de diabetes au moyen de nt-4/5
CA2572193A1 (fr) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Traitement d'etats pathologiques impliquant des oligodendrocytes avec des agents sp35
US7476331B2 (en) * 2005-02-09 2009-01-13 E I Du Pont Nemours And Company Compositions comprising 1,1,1,2,2,3,4,5,5,6,6,7,7,7-tetradecafluoroheptane and uses thereof
WO2006106905A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
AU2006255101A1 (en) 2005-06-06 2006-12-14 Wyeth Anti-TrkB monoclonal antibodies and uses thereof
EP2238986A3 (fr) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Anticorps Sp35 et utilisations associées
WO2007058843A2 (fr) * 2005-11-15 2007-05-24 Lentigen Corporation Conception de vecteur basee sur le web
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2568436T3 (es) * 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (fr) * 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
BRPI0817637A2 (pt) * 2007-09-28 2015-09-08 Chugai Pharmaceutical Co Ltd anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010131733A1 (fr) 2009-05-15 2010-11-18 中外製薬株式会社 Anticorps anti-axl
EP2481752B1 (fr) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Régions constantes modifiées d'un anticorps
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
EP3467501B1 (fr) 2014-05-16 2020-11-04 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
CA2973266A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de demyelinisation
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
EP3279216A4 (fr) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production d'un hétéro-oligomère polypeptidique
JP7023461B2 (ja) 2015-07-28 2022-02-22 オトノミ―，インク． 耳の疾病の処置のためのｔｒｋｂ又はｔｒｋｃアゴニスト組成物及び方法
US10066229B2 (en) 2015-07-28 2018-09-04 Otonomy, Inc. Treatment using truncated Trk B and Trk C antagonists
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
EP3596225A1 (fr) 2017-03-14 2020-01-22 Amgen Inc. Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
EP4034556A1 (fr) 2019-09-26 2022-08-03 Amgen Inc. Procédés de production de compositions d'anticorps
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022081824A1 (fr) 2020-10-15 2022-04-21 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6247647B1 (en) * 1988-09-19 2001-06-19 Symbol Technologies, Inc. Scan pattern generator convertible between multiple and single line patterns
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
JPH0595786A (ja) 1991-10-07 1993-04-20 Green Cross Corp:The 変異ヒトプロウロキナーゼ
US5349055A (en) * 1992-03-06 1994-09-20 Persson Hakan B Nerve growth factor having altered receptor binding specificities
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
ES2196088T3 (es) * 1994-10-13 2003-12-16 Amgen Inc Analogos del factor de crecimiento de los queratinocitos.
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy

Also Published As

Publication number Publication date
CA2259163A1 (fr) 1998-01-29
EP0938499A1 (fr) 1999-09-01
CZ399A3 (cs) 1999-06-16
US6211150B1 (en) 2001-04-03
NO990059D0 (no) 1999-01-07
IL127872A0 (en) 1999-10-28
AU3671297A (en) 1998-02-10
US6500429B2 (en) 2002-12-31
US6723701B2 (en) 2004-04-20
AU720232B2 (en) 2000-05-25
NZ333650A (en) 2000-02-28
WO1998003546A1 (fr) 1998-01-29
NO990059L (no) 1999-03-19
CA2259163C (fr) 2004-07-06
SK1499A3 (en) 1999-08-06
US20050143294A1 (en) 2005-06-30
US20020010135A1 (en) 2002-01-24
US20010027179A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ZA976326B (en) Analogs of cationic proteins.
HUP9904239A3 (en) High level expression of proteins
ZA9710338B (en) Proteins
GB9510830D0 (en) Proteins
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
EP1018551A4 (fr) Proteine megsine
ZA984322B (en) Sucrose-binding proteins
IL115317A0 (en) Proteins
GB9715064D0 (en) Protein expression
GB9413316D0 (en) Novel proteins
GB9720784D0 (en) Protein
IL156970A0 (en) Analogs of cationic proteins
EP0915100A4 (fr) Nouvelle proteine
ZA975001B (en) Preparation of Alpha-fluoroketones.
ZA971900B (en) Modified proteins
GB9703850D0 (en) Novel protein
GB9714075D0 (en) Novel protein
GB9706119D0 (en) Novel protein
GB9703827D0 (en) Novel protein
GB9704252D0 (en) Novel protein
GB9703104D0 (en) Proteins
GB9722003D0 (en) Proteins
GB9722727D0 (en) Proteins
GB9707822D0 (en) Proteins